FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284889639> ?p ?o ?g. }

• W4284889639 abstract "As immune checkpoint inhibitors (ICIs) continue to advance, more evidence has emerged that anti-PD-1/PD-L1 immunotherapy is an effective treatment against cancers. Known as the programmed death ligand-1 (PD-L1), this co-inhibitory ligand contributes to T cell exhaustion by interacting with programmed death-1 (PD-1) receptor. However, cancer-intrinsic signaling pathways of the PD-L1 molecule are not well elucidated. Therefore, the present study aimed to evaluate the regulatory network of PD-L1 and lay the basis of successful use of anti-PD-L1 immunotherapy in acute myeloid leukemia (AML). Data for AML patients were extracted from TCGA and GTEx databases. The downstream signaling pathways of PD-L1 were identified via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The key PD-L1 related genes were selected by weighted gene co-expression network analysis (WGCNA), MCC algorithm and Molecular Complex Detection (MCODE). The CCK-8 assay was used to assess cell proliferation. Flow cytometry was used to determine cell apoptosis and cell cycle. Western blotting was used to identify the expression of the PI3K-AKT signaling pathway. PD-L1 was shown to be elevated in AML patients when compared with the control group, and high PD-L1 expression was associated with poor overall survival rate. The ECM-receptor interaction, as well as the PI3K-AKT signaling pathway, were important PD-L1 downstream pathways. All three analyses found eight genes (ITGA2B, ITGB3, COL6A5, COL6A6, PF4, NMU, AGTR1, F2RL3) to be significantly associated with PD-L1. Knockdown of PD-L1 inhibited AML cell proliferation, induced cell apoptosis and G2/M cell cycle arrest. Importantly, PD-L1 knockdown reduced the expression of PI3K and p-AKT, but PD-L1 overexpression increased their expression. The current study elucidates the main regulatory network and downstream targets of PD-L1 in AML, assisting in the understanding of the underlying mechanism of anti-PD-1/PD-L1 immunotherapy and paving the way for clinical application of ICIs in AML." @default.
• W4284889639 created "2022-07-09" @default.
• W4284889639 creator A5008643939 @default.
• W4284889639 creator A5034306435 @default.
• W4284889639 creator A5042293113 @default.
• W4284889639 creator A5044119010 @default.
• W4284889639 creator A5069451510 @default.
• W4284889639 creator A5069596466 @default.
• W4284889639 creator A5074792881 @default.
• W4284889639 creator A5081752925 @default.
• W4284889639 creator A5089474387 @default.
• W4284889639 date "2022-07-06" @default.
• W4284889639 modified "2023-10-15" @default.
• W4284889639 title "PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway" @default.
• W4284889639 cites W1533942137 @default.
• W4284889639 cites W1568317937 @default.
• W4284889639 cites W1966110583 @default.
• W4284889639 cites W1966327575 @default.
• W4284889639 cites W1988709079 @default.
• W4284889639 cites W1990156180 @default.
• W4284889639 cites W2027847170 @default.
• W4284889639 cites W2035618305 @default.
• W4284889639 cites W2050574097 @default.
• W4284889639 cites W2050999762 @default.
• W4284889639 cites W2062549560 @default.
• W4284889639 cites W2103912979 @default.
• W4284889639 cites W2106657714 @default.
• W4284889639 cites W2108548228 @default.
• W4284889639 cites W2120335772 @default.
• W4284889639 cites W2209812019 @default.
• W4284889639 cites W2256481109 @default.
• W4284889639 cites W2501125746 @default.
• W4284889639 cites W2523826139 @default.
• W4284889639 cites W2554707488 @default.
• W4284889639 cites W2590024745 @default.
• W4284889639 cites W2605967338 @default.
• W4284889639 cites W2739584564 @default.
• W4284889639 cites W2776548546 @default.
• W4284889639 cites W2790226786 @default.
• W4284889639 cites W2794346955 @default.
• W4284889639 cites W2889532022 @default.
• W4284889639 cites W2890296921 @default.
• W4284889639 cites W2890371056 @default.
• W4284889639 cites W2908717823 @default.
• W4284889639 cites W2912990831 @default.
• W4284889639 cites W2914626281 @default.
• W4284889639 cites W2950408983 @default.
• W4284889639 cites W2967125546 @default.
• W4284889639 cites W2981291815 @default.
• W4284889639 cites W2992546630 @default.
• W4284889639 cites W2992790847 @default.
• W4284889639 cites W3005233576 @default.
• W4284889639 cites W3018726844 @default.
• W4284889639 cites W3021497536 @default.
• W4284889639 cites W3039726497 @default.
• W4284889639 cites W3046869151 @default.
• W4284889639 cites W3048644341 @default.
• W4284889639 cites W3083147931 @default.
• W4284889639 cites W3097379412 @default.
• W4284889639 cites W3098118704 @default.
• W4284889639 cites W3109846914 @default.
• W4284889639 cites W3138985279 @default.
• W4284889639 doi "https://doi.org/10.1038/s41598-022-15020-0" @default.
• W4284889639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35794161" @default.
• W4284889639 hasPublicationYear "2022" @default.
• W4284889639 type Work @default.
• W4284889639 citedByCount "10" @default.
• W4284889639 countsByYear W42848896392022 @default.
• W4284889639 countsByYear W42848896392023 @default.
• W4284889639 crossrefType "journal-article" @default.
• W4284889639 hasAuthorship W4284889639A5008643939 @default.
• W4284889639 hasAuthorship W4284889639A5034306435 @default.
• W4284889639 hasAuthorship W4284889639A5042293113 @default.
• W4284889639 hasAuthorship W4284889639A5044119010 @default.
• W4284889639 hasAuthorship W4284889639A5069451510 @default.
• W4284889639 hasAuthorship W4284889639A5069596466 @default.
• W4284889639 hasAuthorship W4284889639A5074792881 @default.
• W4284889639 hasAuthorship W4284889639A5081752925 @default.
• W4284889639 hasAuthorship W4284889639A5089474387 @default.
• W4284889639 hasBestOaLocation W42848896391 @default.
• W4284889639 hasConcept C104317684 @default.
• W4284889639 hasConcept C150194340 @default.
• W4284889639 hasConcept C152724338 @default.
• W4284889639 hasConcept C162317418 @default.
• W4284889639 hasConcept C203014093 @default.
• W4284889639 hasConcept C2777701055 @default.
• W4284889639 hasConcept C2778461978 @default.
• W4284889639 hasConcept C2778729363 @default.
• W4284889639 hasConcept C2779282312 @default.
• W4284889639 hasConcept C502942594 @default.
• W4284889639 hasConcept C54355233 @default.
• W4284889639 hasConcept C62478195 @default.
• W4284889639 hasConcept C75217442 @default.
• W4284889639 hasConcept C86554907 @default.
• W4284889639 hasConcept C86803240 @default.
• W4284889639 hasConcept C8891405 @default.
• W4284889639 hasConcept C95444343 @default.
• W4284889639 hasConceptScore W4284889639C104317684 @default.
• W4284889639 hasConceptScore W4284889639C150194340 @default.
• W4284889639 hasConceptScore W4284889639C152724338 @default.

• next